Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Fredrik Thoren"'
Autor:
Hiroki Ikeda, Eiichi Araki, Nayyar Iqbal, Niki Arya, Hajime Maeda, Michiko Asano, Fredrik Thoren, Toshihiko Shiraiwa, Chantal Mathieu
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To examine the long‐term efficacy and safety of dapagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor used to treat type 1 diabetes, in the Japanese subpopulation of the DEPICT‐2 study. Materials and Methods Patients with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdd7c07f1a9ecbc384927fadd193496
https://doi.org/10.1111/dom.14362
https://doi.org/10.1111/dom.14362
Autor:
Paresh Dandona, Depict Investigators, Depict, Niki Arya, Simon Heller, Paolo Di Bartolo, Lars Hansen, Richard M. Bergenstal, Eiichi Araki, Moshe Phillip, John Xu, Markus F. Scheerer, Nayyar Iqbal, Chantal Mathieu, Marcus Lind, Fredrik Thoren
Publikováno v:
Diabetes, Obesity & Metabolism
Aims This pooled analysis of the DEPICT-1 and -2 trials aimed to evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). Materials and methods DEPICT-1 and -2 were randomized, double-blind, parallel-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eeabb346397e1e4e7778837ac220da0
https://doi.org/10.1111/dom.14248
https://doi.org/10.1111/dom.14248
Autor:
Johan Jendle, Paresh Dandona, John Xu, Nayyar Iqbal, Enrico Repetto, Markus F. Scheerer, Steven V. Edelman, Per-Henrik Groop, Fredrik Thoren, Moshe Phillip, Pieter Gillard, Chantal Mathieu
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:845-854
Summary Background The DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f7846f46b1b29ed6f481ec3393eac5
https://doi.org/10.1016/s2213-8587(20)30280-1
https://doi.org/10.1016/s2213-8587(20)30280-1
Autor:
Jason Gordon, Amarjeet Tank, Hayley Bennet, Lee Beresford-Hulme, Phil McEwan, Markus F. Scheerer, Thomas Danne, Christopher Edmonds, Fredrik Thoren
Publikováno v:
Diabetes Therapy
Introduction Dapagliflozin is an orally active inhibitor of sodium-glucose co-transporter 2 (SGLT2) that is indicated for use in adults with type 1 diabetes (T1DM) (with a body mass index (BMI) of at least 27 kg/m2 in Europe, no such BMI limit in Jap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c497fa6104ace37b10d6a8d383c672
http://europepmc.org/articles/PMC7192983
http://europepmc.org/articles/PMC7192983
Autor:
Hiroshi Ohashi, Eiichi Araki, Hirotaka Watada, Anna Maria Langkilde, Osamu Tomonaga, Yasuko Uchigata, Michiko Asano, Fredrik Thoren, Toshitaka Yajima, Hyosung Kim, Hitomi Fujii, Tadashi Okabe
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To investigate the safety and tolerability of 5 and 10 mg dapagliflozin added to insulin therapy over 52 weeks in Japanese patients with inadequately controlled type 1 diabetes mellitus (T1DM). Materials and methods This randomized, open‐label
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2310911b14b196e9e322bd4b599cd7a1
https://doi.org/10.1111/dom.13922
https://doi.org/10.1111/dom.13922
Autor:
Hyosung Kim, Shinya Ueda, Michiko Asano, Toshitaka Yajima, David W. Boulton, Weifeng Tang, Fredrik Thoren, Eiichi Araki, Masanari Shiramoto, Hirotaka Watada
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To assess the pharmacokinetics/pharmacodynamics (PK/PD) of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor that increases urinary glucose excretion (UGE) and its major metabolite, dapagliflozin-3-O-glucuronide (D3OG), in Japanese pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba57fbacce583b116c84838b690d928
https://doi.org/10.1111/dom.13593
https://doi.org/10.1111/dom.13593
Autor:
Ian Sabir, Laura M. Dember, Ayman Al-Shurbaji, Steven Fishbane, Brian G. Katona, Nicolas Guzman, Charles A. Herzog, Csaba P. Kovesdy, John Xu, Fredrik Thoren, Michel Jadoul
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Patients with end-stage renal disease (ESRD) on chronic haemodialysis are at an elevated risk of arrhythmias that can increase the risk of sudden cardiac death (SCD) and stroke, along with the need for hospitalisation and interven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ef4d7c89665913e0b3ab4dd2ced5229
https://doi.org/10.1093/ndt/gfab092.0092
https://doi.org/10.1093/ndt/gfab092.0092
Autor:
Hajime Maeda, Nayyar Iqbal, Toshihiko Shiraiwa, Hiroki Ikeda, Chantal Mathieu, Niki Arya, Michiko Asano, Eiichi Araki, Fredrik Thoren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae90f5fe8e822dc0bbf4a9fe0b4daba6
https://doi.org/10.1111/dom.14362/v2/response1
https://doi.org/10.1111/dom.14362/v2/response1
Autor:
Eiichi Araki, Paolo Di Bartolo, Richard M. Bergenstal, John Xu, Markus F. Scheerer, Moshe Phillip, Fredrik Thoren, Chantal Mathieu, Marcus Lind, Nayyar Iqbal, Niki Arya, Simon Heller, Paresh Dandona, Lars Hansen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df78358218d49469c00588601a13086
https://doi.org/10.1111/dom.14248/v3/response1
https://doi.org/10.1111/dom.14248/v3/response1
Autor:
Markus F. Scheerer, Paresh Dandona, Moshe Phillip, Nayyar Iqbal, Enrico Repetto, John Xu, Andreas L. Birkenfeld, Chantal Mathieu, Fredrik Thoren, Troels Krarup Hansen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb8934343196afe830ce9724876163a0
https://doi.org/10.1111/dom.14144/v2/response1
https://doi.org/10.1111/dom.14144/v2/response1